Cardiometabolic Medicines Research
Quality use of medicines and medicines safety is Australia’s 10th National Health Priority. Best-practice pharmacotherapy improves health outcomes for people with cardiovascular disease. However, all too often, people with cardiovascular disease are not accessing or adhering to evidence-based therapy.
What we do
The Cardiometabolic Medicines Research Program, led by A/Prof Michael Falster, uses whole-of-population big health data to improve medicine use and outcomes for people with heart disease in Australia.
We investigate treatment of conditions such as hypertension, diabetes, obesity, acute myocardial infarction, heart failure, atrial fibrillation, as well as people who have recieved surgical interventions. A key focus is on novel therapies used for treatment of interconnected cardiovascular, metabolic and renal conditions – medicines such as GLP-1Ras (e.g. Ozempic, Mounjaro) and SLGT2is (e.g. Jardiance) which have significant clinical benefits, but a ‘chasm’ in best-practice use among people who would benefit the most.
Our research helps ensure the clinical benefits of novel therapies are being realised in Australia - improving population health, and saving hearts, kidneys and lives.
Our multidisciplinary team have leading expertise in cardiometabolic health, pharmacy, advanced pharmacoepidemiologic methods, big data analytics (epidemiology, biostatistics, machine learning), and health policy. Some key areas of interest include:
- Measuring population-level trends and disparities in best-practice medicine use and adherence
- Identifying quality use of medicines at transitions of care (e.g. hospital to community care)
- Evaluating the impact of policy interventions on medicine use and outcomes
- Understanding the impacts of multi-medicine use and polypharmacy
- Measuring comparative effectiveness and rare outcomes of therapies
- Exploring continuity and fragmentation of primary and multidisciplinary care
Our team
Our collaborators
- The George Institute for Global Health
- The University of Sydney
- The University of South Australia
- The Garvan Institute of Medical Research
- St Vincent’s Hospital
- Concord Hospital
- International Centre for Future Health Systems, 鶹madou
- National Drug and Alcohol Research Centre, 鶹madou
- Oxford University, UK
- McGill University, Canada
- University of Copenhagen, Denmark
Select grant and partnership funding
- National Health and Medical Research Council
- National Heart Foundation of Australia
- NSW Ministry of Health
- Centre for Research Excellence in Medicines Intelligence
- 鶹madou Cardiovascular and Metabolic Medicine Theme
- NSW Cardiovascular Research Network
News and stories
Select publications from our team
-
-
-
- Costa JDO; Lin J; Pearson SA; Buckley NA; Schaffer AL; Falster MO; de Oliveira Costa J, 2023, 'Persistence and Adherence to Cardiovascular Medicines in Australia', Journal of the American Heart Association, 12, pp. e030264,
- Falster MO; Garland SK; Jorm LR; Beiles CB; Freeman AJ; Sedrakyan A; Sotade OT; Varcoe RL, 2023, 'Editor's Choice – Comparison of outcomes for major contemporary endograft devices used for endovascular repair of intact abdominal aortic aneurysms', European Journal of Vascular and Endovascular Surgery, 65, pp. 272 - 280,
- Lin J; Pearson SA; Greenfield JR; Park KH; Havard A; Brieger D; Day RO; Falster MO; de Oliveira Costa J, 2023, 'Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022)', European Journal of Clinical Pharmacology, 79, pp. 1239 - 1248,
- de Oliveira Costa J; Pearson SA; Brieger D; Lujic S; Shawon MSR; Jorm LR; van Gool K; Falster MO, 2023, 'In-hospital outcomes by insurance type among patients undergoing percutaneous coronary interventions for acute myocardial infarction in New South Wales public hospitals', International Journal for Equity in Health, 22, pp. 226,
- Milder TY; Greenfield JR; Milder DA, 2023, 'Peri-procedural ketoacidosis risk with sodium-glucose cotransporter 2 inhibitor use in people without diabetes', Anaesthesia, 78, pp. 1418 - 1419,
- Milder TY; Milder DA; Greenfield JR; Day RO, 2023, 'Sodium-Glucose Cotransporter 2 Inhibitor-Associated “Ketoacidosis” Versus “Diabetic Ketoacidosis”: The Importance of Accurate Terminology', Drug Safety, 46, pp. 1303 - 1305,
- Garland SK; Falster MO; Beiles CB; Freeman AJ; Jorm LR; Sedrakyan A; Sotade O; Varcoe RL, 2023, 'Long-Term Outcomes Following Elective Repair of Intact Abdominal Aortic Aneurysms: A Comparison Between Open Surgical and Endovascular Repair Using Linked Administrative and Clinical Registry Data', Annals of Surgery, 277, pp. E955 - E962,
- Mao J; Behrendt CA; Falster MO; Varcoe RL; Zheng X; Peters F; Beiles B; Schermerhorn ML; Jorm L; Beck AW; Sedrakyan A, 2023, 'Long-term Mortality and Reintervention after Endovascular and Open Abdominal Aortic Aneurysm Repairs in Australia, Germany, and the United States', Annals of Surgery, 278, pp. E626 - E633,
- Robijn AL; Filion KB; Woodward M; Hsu B; Chow CK; Pearson SA; Jorm L; Falster MO; Havard A, 2023, 'Comparative effect of varenicline and nicotine patches on preventing repeat cardiovascular events', Heart, 109, pp. 1016 - 1024,
- Sotade OT; Falster MO; Pearson SA; Jorm LR; Sedrakyan A, 2023, 'Comparison of long-term outcomes of bioprosthetic and mechanical aortic valve replacement in patients younger than 65 years', Journal of Thoracic and Cardiovascular Surgery, 166, pp. 728 - 737.e13,
-
-
-